Issues that would cause treatment delays should be discussed with the Principal Investigator . If a patient does not receive protocol therapy following registration, the patient’s registrati on on the study may be canceled. The Study Coordinator should be notif ied of cancellations as soon as possible. 4.1 Registration Process This study is supported by the NCI Ca ncer Trials Support Unit (CTSU). Prior to the recruitment of a patient for this study, invest igators must be registered members of a Cooperative Group. Each inve stigator must have an NCI investigator number and must maintain an “active” investigator registration status through the annual NCI Protocol #: CITN-04 Version Date: 27 Jan 2016 26 submission of a complete investigator regist ration packet (FDA Form 1572 with original signature, current CV, Supplemental Inves tigator Data Form with signature, and Financial Disclosure Form with original si gnature) to the Pharmaceutical Management Branch, CTEP, DCTD, NCI. These forms are available on the CTSU Web site (enter credentials at https://www.ctsu.org ; then click on the Register tab) or by calling the PMB at 301-496-5725 Monday through Friday between 8:30 a.m.